FindTrial
Sign In

Efficacy and safety of anti-MRSA antibiotics for hospital-acquired pneumonia: a systematic review and meta-analysis

Efficacy and safety of anti-MRSA antibiotics for hospital-acquired pneumonia: a systematic review and meta-analysis - Efficacy and safety of anti-MRSA antibiotics for hospital-acquired pneumonia: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000048776
Enrollment
Unknown
Registered
2022-08-27
Start date
2022-08-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospital-acquired pneumonia

Interventions

None listed

Sponsors

NHO Kinki-chuo Chest Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP). HAP and VAP are defined as new-onset pneumonia after 48 hours of hospitalization according to ATS/IDSA 2016 and JRS 2017 guidelines.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Mortality (28-day, 30-day, or in-hospital)—

Countries

Japan

Contacts

Public ContactHiroshi Sugimoto

NHO Kinki-chuo Chest Medical Center Department of Internal Medicine

dr.sugimoto@gmail.com072-252-3021

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026